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Characterization of Cannabinoid Receptor 2 Transcript Expression in
B Cells
Tracy Sherwood
ABSTRACT

Cannabinoids and cannabinoid receptors have been shown to
play important roles in immune regulation particularly as modulators
of anti-inflammatory cytokines and antibody production. The
predominant cannabinoid receptor involved in this immune regulation
is cannabinoid receptor 2 (CB2), which is robustly expressed in B cells.
Utilizing a combination of bioinformatics, 5' RACE, real time RT-qPCR,
and reporter assays, we showed that human B cells from peripheral
blood mononuclear cells (PBMC) expressed one CB2 transcript while
mouse B cells from spleen express three CB2 transcripts. Alignment of
the sequenced B cell RACE products to either the mouse or human
genome, along with the GenBank mRNA sequences, revealed that the
transcripts isolated in this study contained previously unidentified
transcriptional start sites (TSSs). In addition, expression construct
testing of the genomic region containing the TSSs of the mouse CB2
exon 1 and 2 transcripts showed a significant increase of promoter
vii

activity. Bioinformatics analysis for cis-sequences in the promoter
regions identified DNA binding sites for NF-kB, STAT6, and Elk1
transcription factors activated by LPS, IL-4 and anti-CD40. Regarding
variations in CB2 transcript expression among the immune cell
subtypes, RACE analysis showed that the exon 1b transcript is seen in
B cells but not in T cells, dendritic cells or macrophages. Furthermore,
RT-qPCR showed variations in transcript expression during B cell
development as well as in resting versus LPS or IL-4/anti-CD40
stimulated B cells. The exon 1a transcript was predominant in pre-,
immature and resting B cells whereas the exon 1b and 2 transcripts
were enhanced in mature and activated B cells. These data showed for
the first time that human B cells use one TSS for CB2 expression while
mouse B cells use multiple TSSs for the expression of three CB2
transcripts, in which the expression of the individual transcript is
related to immune cell type and/or cell activation state. Additionally,
this is the first report in mouse B cells defining TSSs that are in
genomic areas with promoter activity thus suggesting the location of
two promoter regions. Defining the CB2 transcript expression during
various stages of B cell activation provide clues to therapeutic
methods.

viii

INTRODUCTION

Cannabinoids and Cannabinoid Receptors
The marijuana plant (Cannabis sativa) and preparations derived
from it have been used for medicinal and recreational purposes for
thousands of years. Cannabis produces ~60 unique compounds known
as cannabinoids, of which Δ9-tetrahydrocannabinol (THC) is considered
the most important, owing to its abundance and psychoactive
component (4, 29). Currently two cannabinoid receptors have been
described. Cannabinoid receptor 1 (CB1) the first to be identified (27),
also known as the “central” cannabinoid receptor is found primarily in
the brain and central nervous system (CNS) and is responsible for the
psychoactive effect of THC. CB1 is also found in cells of the male and
female reproductive system, as well as in some peripheral organs,
such as liver, fat and muscle cells. Cannabinoid receptor 2 (CB2) (30),
known as the “peripheral” cannabinoid receptor is almost exclusively
found in the immune system, with highest expression observed in B
cells. It is also found in the peripheral nervous system and in
microglia. CB2 has been shown to be the cannabinoid receptor
1

primarily responsible for the anti-inflammatory and possible immune
therapeutic effects of cannabis (22) (38) (7).
The cannabinoid receptors belong to the G protein-coupled
receptor (GPCR) superfamily, and are seven-transmembrane domain
receptors, which act as a guanine nucleotide exchange factor (GEF) for
associated G-proteins by exchanging bound GDP for GTP. The bound
GTP activates the G-protein by causing the dissociation of the Gprotein’s α-subunit from the β and γ subunits. Two signal transduction
pathways are affected by G-protein activation, the cAMP pathway and
the phosphatidylinositol pathway. Cannabinoid receptors signal
through a Gi/o-protein, in which dissociation of the α-subunit inhibits
adenylate cyclase and thereby decreasing the production of cyclic AMP
(19) (18) (2).
The cannabinoid receptors are activated by three general types
of cannabinoids: 1. Phytocannabinoids, also known as the classical
cannabinoids, which 66 have been isolated from Cannabis. 2.
Endocannabinoids, produced endogenously by the body, in which two
have been well characterized, arachidonolyethanolamine (Anandamide
or AEA) and 2-arachidonynoyl glycerol (2-AG) endogenous. 3.
Synthetic cannabinoids that are useful in experiments to determine
receptor function. Numerous agonists have been design, some non2

selective, such as CP-55940, that bind CB1 and CB2 with similar
affinity, as well as selective agonists, such as JWH-133, which binds
only to CB2. In addition, antagonists have been designed to either
selectively block CB1, SR141716, or CB2, SR144528 (38) (24, 29, 31)
(6).

B cells
B cells are antibody producing lymphocytes (white blood cells)
that make up part of the adaptive immune system and responsible for
the humoral immune response, the portion of immunity that is
mediated by antibodies. On the surface of every B cell is a membranebound immunoglobulin (Ig) receptor, the B cell receptor (BCR), which
binds to specific antigen. It is the BCR and the ability of the receptor to
recognize antigen in its native form, as well as the maturation and
production of large amounts of antibodies that distinguishes B cells
from other types of lymphocytes. The “B” comes for the bursa of
Fabricius, an organ in birds that is the site of hematopoiesis and B cell
development and maturation. In mammals, the bone marrow is the
site of hematopoiesis and where B cells are continually produced.
Development occurs through several stages, each stage representing a
change in the genome content at the Ig loci (Table 1). At the
3

immature stage B cells migrate to the spleen where the final stage of
maturation occurs (3). Mature B cells express both surface IgM and
IgD and are considered naïve until activated by antigen, which can
occur either in a T cell-dependent or –independent manner(15).
The BCR and secreted antibody are comprised of four
polypeptide chains, two identical heavy and two identical light chains
with both constant (C) and variable (V) regions. In the heavy chain V
region there are three segments; Variable (V), Diversity (D), and
Joining (J), whereas light chain only contains V and J. Germ line DNA
has up to 200 V genes, twelve D genes, and four J genes, which during
B cell development randomly rearrange and recombine by a
mechanism known as VDJ recombination to produce functional VDJ
genes. The kappa (κ) and lambda (λ) chains of the Ig light chain loci
rearrange similarly, except the light chain lacks a D gene. The first
step of recombination for the light chain involves joining of V and J to
give VJ before the addition C during transcription (14). Translation of
the spliced mRNA for either Κ or λ results in formation of either the Igκ
or Igλ light chain. At this point, the mature B cell is considered naïve
until it is activated by antigen.
The five classes of antibody; IgA, IgD, IgE, IgG and IgM
respectfully, are defined by the constant regions of the Ig heavy chain.
4

Upon exposure to antigen, naïve mature B cells are activated in the
absence of T cell help (T cell-independent) by antigen cross-linking
(48) of the IgM BCR and differentiate into functional IgM secreting
plasma B cells (primary response). However, most antigens are T celldependent and require T cell help for maximum antibody production.
Antigen primed TH2 helper cells activate B cells through T cell Receptor
(TCR) recognition of specific antigen presented on B cell MHC II, along
with co-stimulation of CD40 on B cells by CD40 ligand on T cells (34).
Cytokines are then secreted by T cells that bind to cytokine receptors
on B cells and trigger B cell proliferation and differentiation into
plasma and memory B cells. In addition, some of the functionally
responsive IgM and IgD expressing mature B cells will undergo the
process of Ig Class Switch Recombination (CSR) (46), in which
rearrangement of the DNA places the recombined VDJ gene next to
either IgG, IgE or IgA C gene, to produce Ig isotype specific secreting
plasma and memory B cells (9). Each isotype has a distinct function,
therefore the type of antigen and cytokines present in the B cell
environment will determine which Ig isotype will be expressed in the
differentiated plasma and memory B cells (Table 2). The memory B
cells, formed from activated B cells, have BCRs that are antigen

5

specific so when exposed to the same antigen, a rapid and effective
immune response occurs (secondary response) (45).

Table 1. B cell Developmental Stages.
Stage

Heavy Chain

Light Chain

Ig

Progenitor

Germline

germline

-

Early Pro

D-J rearrangement

germline

-

Late Pro

V-DJ rearrangement

germline

-

Large Pre

VDJ rearranged

germline

IgM in cytoplasm

Small Pre

VDJ rearranged

V-J rearrangement

IgM in cytoplasm

Immature

VDJ rearranged

VJ rearranged

Surface IgM

Mature

VDJ rearranged

VJ rearranged

Surface IgM & IgD

Table 2. Cytokines responsible for Ig class switching in mouse
Ig isotypes
T cell

Cytokine
IgG1
IL-4

TH2

IgG2a

IgG2b

IgG3

+

IFNγ

Treg

TGFβ

IgE
+

IL-5

TH1

IgA

+
+
+

+, indicates Ig that cytokine induces switching from IgM
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+

Cannabinoid Effects on B cells
The molecular events of the peripheral cannabinoid receptor
(CB2) in immune cell function are still not fully understood. Nor are the
mechanisms that regulate the CB2 gene, Cnr2, during activation of
immune cells. CB2 message expression shows a pattern of mRNA
expression that is most abundant in B cells followed by macrophages
and then T cells (16, 25). Evidence also suggests that anti-CD40 (25),
as well as IL-4 through activation of STAT6 (42), up regulate CB2
message expression and that LPS (25) down regulates its message
expression in B cells; however the mechanisms are still unclear.
Furthermore, CB2 has been implicated in B cell differentiation (8),
migration (20, 39), proliferation (1, 13) and immunoglobulin isotype
switching (1). These findings suggest a role of CB2 as an
immunomodulator. However, many gaps still exist in our
understanding of this receptor’s role in immune cell function, and in
particular how is CB2 receptor expression regulated in B cells.

Gene Regulation
The modern working definition of a gene is “a locatable
region of genomic sequence, corresponding to a unit of inheritance,
which is associated with regulatory regions, transcribed regions, and
7

or other functional sequence regions” (35, 36). A gene is basically a
DNA sequence that contains the instructions for the production of a
protein. The basic gene structure consists of a promoter regulatory
region, and a transcribe region of exons (coding sequences) and
introns (non-coding sequences) (40). Transcription is the first step
leading to gene expression resulting in messenger RNA (mRNA), which
is translated into protein (28). During transcription of a gene, the DNA
sequence is targeted by RNA polymerase II (Pol II), which produces a
complementary pre-mRNA strand, except that uracil (U) is used
instead of thymine (T). The pre-mRNA strand is then spliced to form
the mature mRNA strand that transports to the cytoplasm to be
translated into protein. This process of DNA to RNA to protein is known
as the “central dogma” of biology (Figure 1) (11).

Figure 1. The “Central Dogma” of Biology. Several steps are involved in
gene expression of a protein. Promoters and enhancers regulate what DNA
sequence will be transcribed into pre-mRNA, which is then spliced into mRNA
and translated into protein. This figure was obtained with permission from
Wikimedia Commons.

8

The promoter is typically upstream adjacent to the gene and
contains specific DNA cis-sequences, which provide binding sites for
RNA Pol II and transcription factors (trans-factors). The promoter
consists of two interacting components, the core promoter and the
proximal promoter (51). The core promoter sequence is the minimal
region of DNA required for Pol II to assemble with the basic transfactors and form the pre-initiation complex for initiation of activatorindependent (basal) transcription (17, 43). At the center of the core
promoter sequence is the initiator (INR) sequence that contains the
transcription start site (TSS), which is defined as the most 5’
nucleotide of mRNA transcribed by Pol II (17, 41). The core promoter
also contains the cis-sequences for the basic trans-factor elements,
such as the TATA-box, the TFIIB recognition element (BRE) and the
downstream promoter element (DPE), in which the TSS (+1)
designates their position (Figure 2, provided by Wikimedia Commons)
(43) (21). Cis-sequences upstream of the TSS are negative numbers
counting back from -1, whereas downstream cis-sequences are
positive numbers counting from the TSS (+1). The proximal promoter
is the region generally upstream of the gene that contains regulatory
elements involved in increasing transcription. These regulatory
elements, also known as enhancers/repressors, can be several
9

kilobases (kb) away from the TSS. The large protein transcriptional
complex, causes the DNA to bend back allowing for the placement of
regulatory sequences far from the TSS (51).

+1

BREu
-38 to -32

TATA

BREd

-31 to -24 -23 to -17

INR

DPE

-2 to +5

+28 to +34

Figure 2. The Basic Core Promoter Elements. BRE, TFIIB recognition
element, u upstream, d downstream TATA-box; DPE, downstream promoter
element; INR, initiator; TATA, TATA-box

10

PROJECT SIGNIFICANCE

For centuries marijuana has been used recreationally and as a
therapeutic for many ailments. However, little research was done
investigating the beneficial medical effects of marijuana, until the
discovery of the cannabinoid receptors and the endocannabinoid
system. Since their discovery research in the field has grown
exponentially. In which, recent developments have shown
cannabinoids to be potent anti-inflammatory and immunosuppressive
agents that mediate beneficial effects for many inflammatory diseases,
including multiple sclerosis (10, 32, 33) rheumatoid arthritis, as well
as allergy, an area of cannabinoid research in lab. Previous work done
in our lab by Agudelo et al. 2008, showed that cannabinoids enhanced
the IL-4/anti-CD40 mediated isotype switching from IgM to IgE in
purified mouse B cells. In which, CB2 was implicated as the main
cannabinoid receptor mediating the observed enhanced increase of IgE
in IL-4/anti-CD40 stimulated B cells.
The gene encoding for CB2 is the CNR2 gene, however the
regulatory elements such as the promoter, transcriptional start site
11

(TSS), and cis/trans-factors have not been described in B cells.
Therefore, research is needed to identify these gene regulatory
elements responsible for the expression of CB2 in B cells. The
identification of the gene regulatory elements will lead to a better
understanding of the pathways of CB2 expression and the mechanisms
of increased receptor expression with changes in B cell activity.
Identification of CB2 regulatory elements may also provide clues to
how gene and protein expression can be therapeutically regulated in B
cells. We propose to identify the location and sequence of the core
promoter region(s) of the CNR2 gene in mouse and human B cells as
well as some of the associated proximal promoter elements. Because
CB2 is expressed highest in B cells, it is possible these cells contain
unique features of the promoter contributing to enhanced CB2
transcription.

12

OBJECTIVES

The focus of this project is to determine the Cnr2 gene
transcription start site (TSS) and associated promoter and cissequences involved in CB2 mRNA expression in B cells as well as
investigate transcript usage in resting and activated cells. Previous
studies suggest a role of CB2 in the immune regulation of B cells by
demonstrating involvement in B cell differentiation, migration,
proliferation, and immunoglobulin class switching to IgE. A preliminary
computational analysis of the murine Cnr2 gene and GenBank CB2
mRNA clones revealed that two alternate transcripts containing
different 5’UTR first exons (1 and 2) were reported. Three clones from
immune tissues contained the exon 1 5’UTR, whereas clones
originating from bone and liver contained the exon 2 5’UTR. This
analysis indicated that more than one transcript is produced from the
Cnr2 gene, and that the transcripts may be related to cell type or
function. From this, we hypothesize that the Cnr2 gene encodes
multiple transcripts in B cells and other immune cells, which
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are varied following changes in cell function. In order to test this
hypothesis, we propose the following aims:

Aim 1. To Determine the Extent of CB2 Transcript Expression
and TSSs in B cells
Evidence in the genomic databases suggested the occurrence of
multiple CB2 transcripts utilizing different first exons in various mouse
tissues, as mentioned above. It is well known that the TSS is located
either at the beginning of the first exon or upstream from it. Since 2
first exons (exon 1 and 2) have been reported, B cells possibly express
multiple TSSs and CB2 transcripts employing different first exons.
Therefore, we will explore this possibility in resting B cells. To
accomplish this aim, we will use the Switching Mechanism At 5’ end of
RNA Transcript – Rapid Amplification of cDNA Ends (SMART 5’ RACE)
to identify the number and location of the CB2 TSSs in splenic and
PBMC B cells.

Aim 2. To Characterize the Cnr2 Gene Promoter in B Cells
It has been well established that accurate identification of the
TSS leads to the location of the core promoter, which is usually -40 bp
upstream to +40 bp downstream of the TSS. The basic elements that
comprise the core promoter are the TATA-box, INR (Initiator), DPE
14

(downstream promoter element), and BRE (TFIIB recognition
elements) (41). Identifying the promoter will lead to a better
understanding of how the Cnr2 gene is regulated in B cells, which in
turn will lead to the elucidation of the mechanisms involved in the
immunobiology of CB2 and B cells. We will start with a bioinformatics
analysis using web based analytical tools, such as Genomatix, to locate
the putative promoter regions of the Cnr2 gene. These will then be
cloned into luciferase reporter gene expression vectors and transfected
into purified splenic B cells to test for promoter activity. Truncations of
the clones will be performed to identify core promoter and cisregulatory sequences.

Aim 3. To Determine CB2 Transcript Usage in Activated B cells
as well as Other Immune Cell Subtypes
Since CB2 is abundant in B cells and implicated in the
involvement of various B cell functions, an understanding of transcript
usage under varying conditions of B cell activation will be of value in
designing future studies to regulate CB2 expression. The GenBank data
show that multiple CB2 transcripts exists therefore, some of these
could be unique to B cells and the various associated 5’ UTR sequences
could provide useful targets for selectively suppressing or enhancing
receptor expression in B cells. In this aim, we will compare CB2
15

transcript usage in resting and stimulated B cells. The literature shows
that stimulation of B cells with anti-CD40 and/or IL-4, through STAT6
activation, increases CB2 expression (8) (25) (1, 42), whereas, LPS
stimulation suppresses expression (26). Therefore, to examine CB2
transcript usage, we will stimulate purified B cells with stimuli reported
to increase CB2 expression, such as IL4 that activates STAT6, antiCD40 that increases NFκB, and LPS, a known B cell mitogen, that
binds to TLR4 and activates NFκB and/or IRF3. However, LPS has been
shown to decrease CB2 message, therefore results from these
experiments may uncover possible repressor elements. To perform
these experiments, B cells will be isolated and cultured alone or with
the various stimuli, and analyzed by RT-qPCR at various time points
following B cell stimulation.
Since we would like to know if any of the CB2 transcripts are
unique in B cells, we will also analyze other immune cell subtypes,
such as T cells, dendritic cells and macrophages for the presence of
CB2 transcript variants.

16

MATERIALS AND METHODS

Bioinformatics Analysis
The bioinformatics programs used for this study include the
Genetics Computer Group (GCG) SeqWeb v3.1 software package,
Primer3, the Genomatix Suite, Consite, the Database of Transcriptional
Start Sites (DBTSS), Ensembl and NCBI databases.

Mice
C57BL/6 mice, 8 to 10 wks old, and of mixed gender where
obtained from NCI (Fredericksburg, MD) and housed and cared for in
the University of South Florida Health Science Center animal facility,
which is fully accredited by the American Association for Accreditation
of Laboratory Animal Care.

Isolation of Mouse Splenocytes, T and B cells
Mice were euthanized by CO2 asphyxiation, followed by removal
of the spleens, which were placed in 12 ml of Hanks balanced buffer
saline (HBBS) then pulverized with a Seward Stomacher® 80 (Lab
17

System, England) to release the splenocytes. The splenocytes where
collected by centrifugation at 1100 rpm for 10 minutes at 10°C, and
washed once with PBS. The T and B cells were then isolated by
magnetic negative selection using the EasySep® mouse T or B cell
enrichment Kits (StemCell Technologies, Canada) following the
manufacturer’s protocol. Total RNA was extracted from the
lymphocytes immediately following isolation, except for B cells
activated by LPS (5 μg/ml) for up to 8 hrs.

Human Subjects, Isolation of PBMCs and B cells
Human subjects recruited for this study were male and female
laboratory workers at the University of South Florida, who gave
informed consent. Venous blood (25 ml) was drawn into 4 K3 EDTA
vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ), then diluted
1:1 or 1:2 with RPMI 1640 medium (Sigma, St Louis, MO). The PBMCs
were isolated from blood using Hisopaque®-1077 (Sigma Diagnostics,
Inc.) following the manufacturer’s protocol. B cell isolation was
performed by magnetic negative selection using the EasySep® human
B cell enrichment kit (StemCell Technologies, Canada).

18

Phenotypic Analysis of Immune Cell Populations
Mouse T and B cell subtypes were analyzed for enrichment by
PCR and FACS analysis. RACE cDNA of the T and B cell samples was
analyzed by PCR amplification using specific primers for the CD3ε chain
of the T cell receptor and for the B cell marker CD19 (50). Enrichment
of the B cell preparation is determined by the absence of CD3ε, while T
cell enrichment is determined by the absence of CD19. PCR
amplification was performed using 1 μl of RACE cDNA, 500 nM of each
primer and Taq polymerase supplied with the SMART RACE cDNA
Amplification kit (Clontech Inc., Madison, WI) in a final volume of 25
μl. Amplification was for 28 cycles using the MyCycler™ thermal cycler
(Bio-Rad Laboratories, Hercules, CA). β-actin was used as a loading
control. FACS analysis of the purified mouse T and B cell populations
was done by labeling 106 cells with fluorochrome-conjugated antimouse mAbs; CD19-PE, CD3-PerCP, NK-pan-FITC and F/480-APC (BD
Pharmingen, San Jose, CA). The human B cell populations were
analyzed for enrichment by labeling 105 cells with fluorochromeconjugated anti-human mAbs; CD19-PE, CD3-FITC and CD14-APC (BD
Pharmingen, San Jose, CA). All flow cytometric analysis was conducted
using a FACS Caliber flow cytometer and Cell Quest software (Becton
Dickinson, San Diego, CA, USA).
19

RNA Extraction
Total RNA was extracted from the cell populations by standard
techniques using Tri-reagent (Sigma; 1 ml per 107 cells) and
quantitated using the RiboGreen RNA Quantitation Kit (Molecular
Probes, Eugene, OR). Just prior to cDNA synthesis, residual DNA was
removed by treatment with Turbo DNA-free™ (Ambion Inc., Austin,
TX) following manufacturer’s protocol.

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
To synthesize the cDNA, 1.0 μg of the DNAse treated RNA was
primed with 1 μl of random primers for 5 minutes at 70°C, then
reverse transcribed (RT) at 37°C for 1hr using 15 U avian
myeloblastosis virus (AMV), 40 Units RNasin (Promega, Corp.,
Madison, WI ) and 1.25 mM mix of dNTPs (Promega Corp., Madison,
WI) in a volume of 20 μl. The PCR reaction was carried out in 25 μl
containing 1 μl cDNA, 500 nM of each primer (see Table 2), with 12.5
μl GoTaq Green Master Mix (Promega Corp., Madison, WI) and
amplified using the MyCycler™ thermal cycler (Bio-Rad Laboratories,
Hercules, CA). The PCR amplification conditions were as follows; for
the initial denaturation step, 95°C for 1 min, followed by 32 cycles at
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95°C for 20 sec, 55°C for 30 sec, 72°C for 45 sec, with a final
elongation at 72°C for 3 min.

SMART-5’-RACE
To identify the TSS we employed the technique; Switching
Mechanism At 5’ end of RNA Transcript Rapid Amplification of cDNA
Ends (SMART™ RACE cDNA Amplification kit, Clontech Inc., Madison,
WI) following manufacturer’s protocol. Two reverse gene specific
primers (GSP) were designed, for both mouse and human CB2 using
the GCG SeqWeb v3.1 software (see Table 3 for primer sequences).
The mGSP1 (mCB2-R301) binds within the ORF 301bp downstream of
the ATG, while the hGSP1 (hCB2-R298) binds 298bp downstream of
the ATG. These were used with the universal primer mix (UPM) that
anneals to the SMART sequence at the 5’ end of the cDNA supplied by
the kit for the initial PCR reaction. A second GSP2 (mCB2-R217 and
hCB2-R163), located 84bp upstream of mGSP1, and 74bp upstream of
hGSP1, was used with UPM in a nested PCR for CB2 confirmation. RACE
products were run on a 2% agarose gel, visualized with ethidium
bromide and purified using the Perfectprep® Gel Cleanup kit
(Eppendorf, North America) following manufacturer’s protocol, and
sent to the Moffitt/USF Molecule Biology Core lab for DNA sequencing.
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The SeqWeb PileUp program was used to compare the RACE
sequences with the GenBank mCnr2 and hCNR2 sequences to confirm
CB2 identity, exon usage, and location of the TSSs (Figures 8, 9, and
10).

Table 3. SMART 5’ RACE Primers Used to Identify the TSS.
Gene Specific
Primersa
mGSP1-R301
mGSP2-R217
hGSP1-R298
hGSP2-R163

Sequence 5’-to-3’
CGACCCCGTGGAAGACGTGGAAGATGACAA
TGAACAGGTACGAGGGCTTTCT
GCCAGGAAGTCAGCCCCAGCCAAGCTGCCAA
GCACAGCCACGTTCTCCAGGGCACTTAGCA

5’ binding
siteb
301 bp
217 bp
298 bp
163 bp

a

GSP, gene specific primer; 1 denotes for the initial RACE PCR, 2 used for
nested PCR.
b
The number of base pairs from the start of translation in which the 5’ end
of the GSP binds for amplification of CB2.

PCR and RT-PCR Primer Mapping
Genomic DNA was extracted from mouse splenic and human
peripheral B cells using the Wizard® Genomic DNA Isolation System
(Promega Corp., Madison, WI) following manufacturer’s protocol. RNA
was extracted, DNAse treated and reverse transcribed from mouse and
human B cells as stated above. Using Primer3, forward primers were
designed to flank the TSSs identified by 5’RACE (Figures 11 & 12) 2 to
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10bp in either direction. Forward primers upstream the TSS should
only amplify genomic DNA, whereas forward primers downstream of
the TSS should amplify genomic DNA as well as cDNA derived from the
CB2 transcripts. The PCR reaction was carried out in 25 μl containing
either 1 μl cDNA or 1 μl DNA, 500 nM of each primer (see Table 4),
with 12.5 μl GoTaq Green Master Mix (Promega Corp.) and amplified
using the MyCycler™ thermal cycler (Bio-Rad Laboratories, Inc). The
PCR amplification conditions were as stated in section 2.6 with minor
adjustments, the cycle number was increased to 35 and for the mouse
samples elongation was increased to 1.5 minutes.

Table 4. Primers Used for Mapping the TSSs.
Primer Groupa

Sequence 5’-to-3’b

Assayc

Size of
amplicon

mE1b

ggaggaggcatgaggca
ACACATAGCCTGGCACA
GCGGTTGAATTCTCTCTTC
GACAAAGTTGCAGGCGAAGATCAC
atacatcaaacacatccttg
TTCTAGAAGGCACCCATGT
CCTCTGCTCATTCAGGTACA
GACAAAGTTGCAGGCGAAGATCAC
gcaagagaaagctggctt
TCAACAGGTGCTCTGAGTG
CTGAGGAGTCCCAGTTGTT

PCR
RT-PCR

189 bp
171 bp

PCR
RT-PCR

755 bp
224 bp
189 bp

PCR
RT-PCR

567 bp
99 bp
71 bp

mE2

hE1
a

DNA
mRNA

A
B
C
G
DNA D
mRNA E
F
G
DNA J
mRNA I
H

m, mouse; h, human; E1b, exon 1b; E2, exon 2; A, D, J, DNA forward
primers; B, E, I, forward primers for amplification of mRNA derived cDNA; C,
F, G, H, reverse primers.
b
Primers designed to bind genomic DNA 5’ of the TSSs are in lower case.
c
RT-PCR, reverse transcription polymerase chain reaction.
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Quantitative Real Time RT-PCR (RT-qPCR)
mCB2 transcript exonal usage in resting, LPS (5μg/ml) and IL4/anti-CD40 (3ng/ml, 0.5μg/ml) stimulated splenic B cells was
measured by RT-qPCR, in which we employed a duplex Taqman PCR
strategy; 4 mCB2 exon specific primer sets and probes were designed,
one each for the mCB2 exons (1a, 1b, 2, and 3) and 1 primer and
probe set for the endogenous β-actin control using Primer3 (see Table
5 for primer/probe sequences). The real-time PCR was carried out in
20 μl containing 1 μl cDNA, 300 nM β-actin and 500 nM CB2 primers,
250 nM fluorescent probe (6-FAM for mCB2 exon, ROX for β-actin),
with 10 μl IQ™ Multiplex Powermix, and performed in the iCycler IQ™
Real-Time PCR detection system (Bio-Rad Laboratories, Inc). In brief,
the reaction was performed in duplicate for each RT cDNA product (see
above). Samples were heated for 10 min at 95 °C, followed by 50
cycles of amplification for 15 s at 95 °C and 1 min at 60 °C.
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Table 5. Primers and Taqman® Probes Used in This Study.
Primer pairsa
and probe

mCB2-E3
mCB2-E1a
mCB2-E1b
mCB2-E2
β-actin
a

F
R
P
F
R
P
F
R
P
F
R
P
F
R
P

Sequence 5’-to-3’b

Size of
amplicon

GCCGTGCTCTATATTATCCTGTCCTC
GACAAAGTTGCAGGCGAAGATCAC
6FAM-AGAAAGCCCTCGTACCTGTTCATCAGCA-BHQ1
TCATCTGCGAAAGTGTGA
TTGTCCTGGCTATTCTGTATC
6FAM-CTGGAGCTGCAGCTCTTGGGAC-BHQ1
ACACATAGCCTGGCACA
GCGGTTGAATTCTCTCTTC
6FAM-TCAAGTGAGTTGCAGGACAGCATAC-BHQ1
TTCTAGAAGGCACCCATGT
CCTCTGCTCATTCAGGTACA
6FAM-CTTCCTGTTGCTGTGTGCATCCT-BHQ1
GGGAATGGGTCAGAAGGACT
AGGTGTGGTGCCAGATCTTC
ROX-ATGTGGGTGACGAGGCCCAGAGCAA-BHQ2

120 bp
112 bp
171 bp
189 bp
134 bp

E3, exon 3; E1a, exon 1a; E1b, exon 1b; E2, exon 2; F, forward primer; R,
reverse primer; P, Taqman® probe.
b
6FAM, 6-carboxyfluorescein; BHQ1 or 2, Black Hole Quencher®-1 or 2.
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Promoter Cloning
Using genomic DNA extracted from B cells (see above) and the
pGL3-enhancer vector (Promega), clones were constructed to test for
promoter activity surrounding the TSSs of the mouse exon 1 and 2 CB2
transcript variants. The clones included the region from -359 bp to
+205 bp of the TSS (+1) of exon 1a, whereas the exon 2 clones
spanned the region from -189 bp to +205 bp of the exon 2 TSS (+1).
The DNA regions were PCR amplified (see table 6 for primer
sequences) and initially cloned into the pTOPO-Blue TA vector
(Invitrogen) following manufacturer’s protocol, then sub-cloned by
standard methods, into the pGL3-enhancer vector via the Hind III
restriction enzyme site.

Table 6. Promoter Clones and PCR Primers.
Promoter
clone

pGL3-E16
pGL3-E19
pGL3-E25
pGL3-P7
pGL3-P8
pGL3-P10
pGL3-P11
pGL3-P13

Primers

Sequence 5’-to-3’

Promoter region
cloned

Size
(bp)

E1-352F
E1+123R
E1-14F
E1+123R
E1-441F
E1-19R
E2-F189
E2+R36
E2-F90
E2+R36
E2+F13
E2+R205
E2-F189
E2+R101
E2-F25
E2+R101

GGCACATGTCACAGACAA
GCGAAGAGTTAGGGAAGAGT
CCTGCTGGGTCTCCAGAT
GCGAAGAGTTAGGGAAGAGT
GTTCAATTCCCAGCACCC
CCCACGTAGGTCCCAAGAG
CTTGCCAGTTCCCAGTTTCA
CAAGTCACATGGGTGCCTTCT
AGAAGAGGGACTTGCCCAAA
CAAGTCACATGGGTGCCTTCT
TCTAGAAGGCACCCATGTGA
CTGTGCCTCTGCTCATTCAG
CTTGCCAGTTCCCAGTTTCA
AACAGGATGCACACAGCAAC
TCAAACACATCCTTGCCCTA
AACAGGATGCACACAGCAAC

-270 bp to +205 bp
exon 1a TSS(+1)
+68 bp to +205 bp
exon 1a TSS(+1)
-359 bp to +63 bp
exon 1a TSS(+1)
-189 bp to +36 bp
exon 2 TSS(+1)
-90 bp to +36 bp
exon 2 TSS(+1)
+13 bp to +205 bp
exon 2 TSS(+1)
-189 bp to +101 bp
exon 2 TSS(+1)
-25 bp to +101 bp
exon 2 TSS(+1)

475
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137
422
225
126
192
290
126

Transfection of B cells
Primary B cells were cultured for 24 to 48 hrs in RPMI medium
containing 10% FCS, 10 ng/ml IL-4 and 500 ng/ml anti-CD40, then
transfected (107cells/500μl RPMI in 0.4-cm cuvettes) with the pGL3clones (10μg) by electroporation at 250 V and 800 μFarads using the
Gene Pulser (BioRad). The transfected B cells were collected within 18
to 24 hrs after electroporation. For each cell sample a 50 μl aliquot
was removed and mixed with an equal volume of Trypan Blue to
obtain cell number and check viability. Cells were counted using a
hemocytometer and compound light microscope.

Luciferase Reporter Assay
Cell lysates of the transfected cells were analyzed for luciferase
activity using Promega’s Luciferase Assay System, following
manufacturer’s protocol. In brief, cells were collected by centrifugation
at 600 RCF for 10 minutes and washed 1X with PBS. Cells were lysed
using 200 μl of CCLR, of which 20 μl was used for the luciferase assay
and the remaining lysate was stored at -80˚C. Each sample was in
duplicate and luciferase activity was measured using the MLX
luminometer (Dynex Technologies Inc., Chantilly, VA). A standard
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curve was used to measure the amount of lucerifase protein in each
sample.

Activation of B Cells
To activate B cells we used the B cell mitogen, LPS, and known
inducers of immunoglobulin class switching IL-4 and anti-CD40.
Purified primary splenic B cells were cultured in RPMI medium
containing 10% FCS with either 5 μg/ml LPS or 3 ng/ml IL-4 and 0.5
μg/ml anti-CD40 for 1, 3, and 8 hrs. Total RNA was isolated at each
time point and analyzed for transcript expression by RT-qPCR. Relative
transcript expression was determined by the 2-ΔΔCt method, in which βactin was the endogenous control and time 0 (un-stimulated) was the
calibrator.
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RESULTS

Aim 1. To Determine the Extent of CB2 Transcript Expression
and TSSs in B cells.

Bioinformatics Analysis of the CB2 Gene (Cnr2) and GenBank™
Clones.
Since the discovery of CB2, several cDNA clones from various
mouse and human tissues, as well as the complete gene sequence
have been submitted to GenBank and available to researchers. We
therefore took advantage of this resource to gain initial insight as to
how the CB2 receptor gene is expressed in B cells. Initially we explored
genome databases, such as Ensembl and NCBI, to obtain the location
and gene structure of mouse and human CNR2. The mouse Cnr2
(mCnr2) was reported to be located on chromosome 4, 24.7 kb in size,
and produce at least two transcripts containing different 5’
untranslated region (UTR) first exons (Figure 3A & 3B). Whereas
human CNR2 (hCNR2) was reported on chromosome 1, 39.4 kb in
size, and express a single transcript (Figure 4A & 4B). A consensus
was reported among the mouse and human clones in which the ORF,
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encoding CB2 protein, was within a single exon -- exon 3 for mouse
and exon 2 for human (Figures 3 and 4). Further computational
analysis using the GCG SeqWeb package to align the 5’UTR of the
GenBank™ clones, revealed the mouse clones from various immune
tissues share a similar 5’UTR first exon (exon 1) that differed in length
at their most 5’ nucleotide. Similarly, the clones reported from bone
and liver share a second common 5’UTR first exon (exon 2) yet differ
in length at the 5’ nucleotide (Figure 3C). Analysis of human data
(Figure 4C) showed only one full length human CB2 clone containing a
5’UTR first exon (exon 1). This analysis suggested that mCnr2 utilizes
multiple TSSs to produce at least two CB2 transcript variants whereas
the human gene utilizes only one. However, none of this existing data
provided information as to the location of the TSS and CB2 transcript
variants utilized in B cells. Therefore, we began to investigate the TSS
and CB2 transcripts in B cells purified from mouse splenocytes and
human PBMCs.
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A Mouse chromosome 4; D3
NC_000070

135451398

135476122

5’

3’

B mCnr2 gene, 24.7 kb
exon 1

exon 2

exon 3

16369

1

C

ORF

24724

mCB2 exon 1 Transcripts
exon 1
NFS107

ORF

exon 3

1
ORF

Spleen
68
Thymus

ORF
-89

mCB2 exon 2 Transcripts
exon 3

exon 2
ORF

Liver
16369
Bone

ORF
16334

Figure 3. Computational Analysis of the Mouse Cnr2 Gene.
A. Chromosome location of the mCnr2 (GenBank accession no. NC000070).
B. The mCnr2 gene structure. Boxes represent exons, whereas white boxes
are the untranslated region (UTR) and the dark grey shaded area is the
protein coding region. ORF = open reading frame. Dotted lines are introns,
which are spliced out to form mature mRNA. C. GenBank CB2 mRNA
transcripts; mCB2 exon 1 transcripts are expressed in the murine leukemic
cell line NFS107 (GenBank accession nos. X93168, NM009924), the spleen
and thymus (GenBank accession nos. X86405, and AK037898), whereas
mCB2 exon 2 transcripts are expressed in liver and bone (GenBank accession
nos. BC024052 and AK036658).
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A Human chromosome 1; 1p36.11
NC_000001

24073047

24112404

3’

5’

B hCNR2 gene, 39.3 kb
exon 2

exon 1

ORF
37665

39358

1

C hCB2 Transcripts
exon 2

exon 1
HL60

ORF
ORF
ORF

1
37656
37648

ORF

HEK293
Brain
Leukocyte

37620

Figure 4. Computational Analysis of the Human CNR2 Gene.
A. Chromosome location of the hCNR2 (GenBank accession no. NC000001).
B. The hCNR2 gene structure. Boxes represent exons, whereas white boxes
are the untranslated region (UTR) and the dark grey shaded area is the
protein coding region. ORF = open reading frame. Dotted lines are introns,
which are spliced out to form mature mRNA. C. GenBank hCB2 mRNA
transcripts are expressed in the human promyelocytic leukemic cell line
HL60, human embryonic kidney cell line HEK293, brain, and leukocytes
(GenBank accession nos. NM001841, AV430063, BC074767, and AM1568546).
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Phenotype of Lymphocyte Subtypes
Studies have shown that CB2 mRNA is most abundant in mouse
and human B cells (8, 16, 25) and the bioinformatic analysis
performed above revealed that the mCnr2 produces at least two
transcripts, whereas the hCNR2 produces only one (Figures 5 and 6).
However, from the database we could not find any information
pertaining to the location of the TSS or CB2 transcript usage in purified
mouse and human B cells. Therefore, we began an analysis for CB2
transcript initiation and usage in un-stimulated, resting purified B cells
from mouse splenocytes and human PBMCs. T and B cells were
purified using the EasySep® negative selection kits for mouse and
human. Splenocytes from mice and blood mononuclear cells from
humans were processed over antibody affinity columns to remove all
lymphoid subtypes with the exception of B cells and T cells. We then
employed RT-PCR and flow cytometry to determine enrichment of the
lymphocyte subtypes. RT-PCR determined either the presence or
absence of the T cell specific CD3ε message or the B cell specific
message, CD19. Enrichment of the B cell preparation was determined
by the presence of CD19 and absence of CD3ε, whereas T cell
enrichment was determined by the presence of CD3ε and absence of
CD19. PCR amplification was performed using CD3ε and CD19 specific
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primers (50) for 28 cycles, in which weak to no visible CD19 bands
were seen in the T cell populations and weak CD3ε bands were seen in
the B cell population (Figure 5A). Because of the weak bands seen in
the lymphocyte subtypes, we were unable to determine the percent
purification of the lymphocyte subtypes. Therefore, to determine more
precisely the purity of the subtypes, we performed flow cytometry
analysis using CD19 and CD3 fluorescent labeled antibodies and
demonstrated that the mouse B and T cell populations as well as the
human B cell populations were enriched to greater than 95% (Figures
5 and 6). These results show that the purified lymphocyte subtypes
were indeed highly enriched.
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C

β-actin, 133 bp

CD19, 169 bp

n=5

50

0

Splenocytes

B cells

Figure 5. Phenotypic Analysis of Mouse Immune Cell Subtypes.
Mouse B and T cells isolated from splenocytes by affinity purification
(EasySep®) A. RT-PCR for the presence of the CD3ε message in T cells and
for B cell specific marker CD19; β-actin used as loading control. B. Flow
cytometry analysis of lymphocytes treated with CD19-PE, CD3-PerCP, NKpan-FITC and F/480-APC anti-mouse mAbs (FITC and APC data not shown)
to determine lymphocyte enrichment. C. Graph represents data of 5
independent B cell purification procedures (black bar). Grey bars are CD3+
cells.
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B CELLS

PBMCs
1

52

CD3

10

CD19

100
Percent cell population

B

97

n=3

50

0

PBMCs

B cells

Figure 6. Phenotypic Analysis of Lymphocyte Subtypes Isolated from
Human PBMCs.
A. Human B cells isolated from PBMCs by affinity purification were analyzed
with CD19-PE, CD3-FITC and CD14-APC anti-human mAbs (CD14 data not
shown) to determine B cell enrichment. B. Graph represents data from 3
human donors. Black bars are B cells and grey bars are T cells.
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Mouse and Human B cells Differ in the Number of CB2 TSSs.
To determine the location of the mCnr2 TSS in purified B cells,
we employed the SMART 5’ RACE technique. Figure 7 shows RACE
results of RNA isolated from mouse and human B cells. For mouse
cells, we used the GSP1, mCB2-R301, along with the UPM primer
supplied with the kit. RACE PCR yielded three mCB2 transcripts that
were confirmed as CB2 RACE products by nested PCR (Figure 7A).
RACE was also performed on human B cell RNA using the hCB2-R298
GSP1 with the UPM, followed by nested PCR using hCB2-R163 GSP2,
resulting in the demonstration of only one transcript (Figure 7B). In
order to determine the relative gene location of the TSSs and 5’UTR
structure of the CB2 transcripts in B cells, the RACE products were
isolated, sequenced and the nucleotides aligned for analysis. The
location of the TSS was revealed by alignment of the 5’ end of the
RACE sequences with the UPM- SII oligo primer sequence and genomic
DNA (Figure 8). Furthermore, alignment of the sequenced RACE
products to either the mouse or human genome, along with the
GenBank submitted mRNA sequences revealed several new aspects of
CB2 transcript expression in B cells. First the mouse transcripts were
homologous to the Cnr2 as well as the existing CB2 mRNA data, with
the exception that exons 1 and 2 in the transcripts we isolated were
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longer by 14 to 294 nucleotides, respectively, indicating they
contained previously unidentified TSSs. Mouse B cells also expressed
and additional transcript, exon 1b, with three TSSs (Figure 9).
Regarding transcript usage in human B cells, data obtained from three
human subjects showed expression of only one first exon (Figure 10).
To our knowledge, this is the first report identifying TSSs in B cells
from mouse and human and these sequences have been submitted to
GenBank (accession nos. FJ357033-6).
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A. Mouse
1°

2°
exon 1b
exon 2
exon 1a

500 bp

B. Human

1°

500 bp

2°

exon 1

Figure 7. CB2 Transcripts and TSSs Identified by 5’ RACE.
Gel electrophoresis of the 5’ RACE products visualized on a 2% agarose gel
stained with ethidium bromide. primary PCR (1°), nested PCR (2°). A. Mouse
5’ RACE products, 1° product length; exon 1b, 778-788 bp; exon 2, 614 bp;
exon 1a, 543 bp. 2° size; exon 1b, 697-707 bp; exon 2, 533 bp; exon 1a,
459 bp B. Human 5’ RACE product, 1°, 455 bp; 2°, 381 bp.
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Mouse exon 1a RACE products

Cnr2
Spleen
Spleen
B cell
B cell
B cell
B cell
B cell

+1
CACCAGACCTCCTCTCATTCACTCATCTGCGAAAGTGTGAGAGCAAG
AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG
AACGCAGAGTACGCGGTGATCTGCGAAAGTGTGAGAGCAAG
AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG
AACGCAGAGTACGCGGTGATCTGCGAAAGTGTGAGAGCAAG
AAGGCAGAGTAGGGGGTCATCTGCGAAAGTGTGAGAGCAAG
AACGCAGAGTACGCGGGGATCTGCGAAAGTGTGAGAGCAAG
ATCTGCGAAAGTGTGAGAGCAAG

Mouse exon 1b RACE products

Cnr2
Spleen
B cell
B cell
B cell
B cell
B cell
B cell

+1
+1
+1
AGGCATGAGGCACACACATAGCCTGGCACATGTCACAGACAAAAGGATGT
AACGCAGAGTACGACGGGACAGACAGAAGGATGT
ACGCAGAGTACGCGGGGACAGACAAAAGGATGT
CGCAGAGTACGCGGGGACAGACAAAAGGATGT
ACGCAGAGTACGCGGGGACATGTCACAGACAAAAGGATGT
CAAGCAGGGGTATACATACCGTGTCACATGTCACAGACAAAAGGATGT
TACATAGCCTGGCACATGTCACAGACAAAAGGATGT
ACAGCATGGGTATACATAGCGTGGCACAGGTCACAGACAAAAGGATGT

Mouse exon 2 RACE products

Cnr2
Spleen
Spleen
B cell
B cell
B cell

+1
TATACATCAAACACATCCTTGCCCTAGAAATAGGTCTTCTAGAAGGCA
AAGCAGAGTACGCGGGGAGAAATAGGTCTTCTAGAAGGCA
GGGGGAGAAATAGGTCTTCTAGAAGGCA
AAGCCGAGTTCGGCGGGAGAAATAGGTCTTCTAGAAGGCA
ACGCAGAGTACGGCGGGAGAAATAGGTCTTCTAGAAGGCA
GGGGAGAAATAGGTCTTCTAGAAGGCA

Human RACE products

CNR2
B cell
B cell
B cell

+1
AGCAAGAGAAAGCTGGCTTGGGGTGGCACTCAACAGGTGCTCTGAGTG
TACGCGGGGGGCACTCAACAGGTGCTCTGAGTG
CGGGGGGCACTCAACAGGTGCTCTGAGTG
ACGCAGAGTCGCGGGGGCACTCAACAGGTGCTCTGAGTG

Figure 8. 5’ RACE Products Reveal Location of the TSSs. To determine
the TSS, the GCG SeqWeb PileUp program was used to align the 5’ end of
the RACE products with the CNR2 gene and the UPM (AACGCAGAGT)-SII Oligo
(ACGCGGG) sequences supplied with the RACE kit. TSSs are bold underlined
and marked as +1. Shaded grey indicates the kit primers.
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exon 1

exon 2

exon 3
ORF

5’

3’

exon 1b, 652-62bp
exon 1a, 414bp

-294,-282,-275
-14

exon 2,

488bp

Exon 1a: 151 bp
-14
ATCTGCGAAAGTGTGAGAGCAAGAAACCCCAGGCTGGAGCTGCAGCTCTTGGGACCTACG
TGGGGGTCCCTGCTGGGTCTCCAGATCTGGATACAGAATAGCCAGGACAAGGCTCCACAA
GACCCTGGGGCCCAGCGGCTGACAAATGACA

Exon 1b: 412, 419, & 431 bp
-294
-282
-275
ACATAGCGTGGCACATGTCACAGACAAAAGGATGTAAACTTTACAGAGGTCAAGTGAGTT
GCAGGACAGCATACACCCGGGGCCAGATTAGAACCCAAGTTTCTGGAGTCTAAGGTCTAT
GCCTATGCCCTCCCCTGGCCAGAGTTCCTAGGAAGAGAGAATTCAACCGCAGGGCAAGAA
CACTGTGGCACTGAGGACCCAGAGGGGAAGTGGTAACCGGTACGGAAGGCCAGATCTCCT
CTCACTCACTTATCTGCACCAGACCTCCTCTCATTCACTCATTTGCGAAAGTGTGAGAGC
AAGAAACCCCAGGCTGGAGCTGCAGCTCTTGGGACCTACGTGGGGGTCCCTGCTGGGTCT
CCAGATCTGGATACAGAATAGCCAGGACAAGGCTCCACAAGACCCTGGGGCCCAGCGGCT
GACAAATGACA

Exon 2: 253 bp
-172
AGAAATAGGTCTTCTAGAAGGCACCCATGTGACTTGCAGAGGGTATCTCTATCTTCGTGG
AGACAGGGAGCCGGGCTTCCTGTTGCTGTGTGCATCCTGTTGTTCTCTTGTTAGGATGTC
CATCAAATGCATGCATTTCCTTTCCTAACTCTGGACAGTAACAGTCGTCTGCGGCCAAGC
TGTGCCTGAATGAGCAGAGGCACAGGCACCAGCCGTGGCCACCCAGCAAACATCTCTGCT
GACTCAGACTGGG

Figure 9. The Cnr2 Gene Location of the TSSs and 5’UTR Sequences
Identified by 5’ RACE. CB2 transcripts are labeled with their corresponding
exon along with the number of nucleotides sequenced for each RACE product.
The upward arrows represent the Cnr2 gene location of the TSSs (underlined
nucleotide) relative to position 1 (bold underlined nucleotide) of the
Genbank™ accession nos. NM009924 for exons 1a & 1b and BC024052 for
exon 2. Small black arrows mark the relative location of the GSPs. The 5’UTR
exon sequences of the mCB2 transcripts submitted to GenBank (accession
nos. FJ357033-5).
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exon 2
3’

exon 1

ORF

5’
exon 1, 410bp
-35

Exon 1: 117 bp
GGGTGTGTTGTGGGTGGCTGGGCACTGGGAGCTGCCGGGGGGTGAGGAGTCCC
AGTTGTTTTTTGTCCTCTCCCAGGACCTGGCCGTGGGTGCCACTCAGAGCACC
TGTTGAGTGCC
-35

Figure 10. Human CB2 5’RACE Transcripts have a Single TSS and
5’UTR. The CNR2 gene location of the TSS (upward arrow). Number below
the arrow represents the location of the TSS (underlined nucleotide) relative
to position 1 (bold underlined nucleotide) of Genbank™ accession no.
NM001841. Small black arrows mark the relative location of the GSPs. The
CB2 5’UTR exon 1 sequence submitted to GenBank (accession no. FJ357036).
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To verify the relative location of the TSSs, we designed specific
forward primers for PCR of either genomic DNA or cDNA reverse
transcribed from 1 μg of total RNA. The strategy for these experiments
is illustrated in figures 11A and 12A. In brief, the forward primers were
designed so that either the 3’ or 5’ end borders the TSS.
Consequently, the forward primer in which the 3’ end is adjacent to
the TSS will only amplify genomic DNA and not the cDNA derived from
the mRNA transcripts, whereas the forward primer that adjoins the
TSS at the 5’ end will amplify both genomic DNA and cDNA. There is
some limitation with this approach in that it is not as sensitive as 5’
RACE in determining the TSS, but it does help confirm the relative
location of the TSS and approximate 5’ end of the transcripts.
Therefore, using this approach we were able to confirm the TSS
location of mCB2 exons 1b and 2 (Figure 11B), as well as the hCB2
exon 1 transcript (Figure 12B). Another limitation with the assay was
that mouse exons 1a and 1b share identical sequences with the
exception that exon 1b is 280 nucleotides longer at the 5’ end.
Consequently, primers designed to adjoin the TSS of exon 1a would
not be able to distinguish genomic DNA from cDNA derived from exon
1b and would amplify both. Therefore, we could not use this approach
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to verify the location of the TSS for transcripts containing exon 1a in B
cells.
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Figure 11. Primer Mapping of the mCB2 TSSs. A. Illustration of the
strategy for primer mapping of the mCB2 TSSs. Forward primers A and D
(black arrows) only amplify genomic DNA while forward primers B and E
(grey arrows) amplify both genomic DNA and cDNA derived from CB2 mRNA.
The reverse primers C, F, and G (grey arrows) are shown. The blown out
sequences illustrate where the forward primers bind in relation to the TSSs.
The bold letters are the 3’ and 5’ end of the forward primers, and underlined
nucleotides are the TSS B. Gel electrophoresis of the mapped CB2 transcripts,
where in lane 1 contains cDNA derived from 1 μg of total RNA from mouse
splenic B cells, lane 2 is genomic DNA extracted from B cells, and lane 3
contains the no template control. The bands are labeled with the primer pair
(white letters) used for PCR amplification. The panels are labeled with the
exon TSS tested.
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Figure 12. Primer Mapping of hCB2 TSS. A. Forward primer J (black
arrow) only amplifies genomic DNA and forward primer I (grey arrow)
amplifies both genomic DNA and the cDNA derived from CB2 mRNA. The
reverse primer H (grey arrow) is shown. The blown out sequence illustrates
where the forward primers bind in relation to the TSSs. The bold letters are
the 3’ and 5’ end of the forward primers, and the underlined nucleotide is the
TSS. B. Gel electrophoresis of the mapped hCB2 transcript, where in lane 1
contains cDNA derived from 1 μg of total RNA from human PBMC B cells, lane
2 is genomic DNA extracted from B cells, and lane 3 contains the no template
control. The primers used for each PCR are labeled in white above the bands.
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Preferential Usage of the CB2 Exon 1a Transcript Variant in
Resting Splenic B Cells
The 5’ RACE data revealed that resting splenic B cells expressed
several CB2 transcripts. Therefore, in order to determine which
transcript was most abundant we used RT-PCR to quantify the
transcripts. Using exon specific primers, semi-quantitative RT-PCR
showed exon 3-containing transcripts and those containing variants of
exon 1 rather than exon 2 predominated in resting B cells (Figure
13A). To better define these results we used quantitative real time RTPCR (RT-qPCR). The primers and CB2 exon specific taqman sequences,
listed in table 5 and located as black boxes in the diagram of figure 13,
were used in conjunction with β-actin primers and taqman probe in a
duplex RT-qPCR. Since all three transcripts include exon 3, primers
designed for this exon will amplify all the transcripts regardless of the
first exon. In addition primers designed for exon 1a should amplify all
transcripts containing exon 1, whereas primers for exon 1b and 2 were
designed to specifically amplify transcripts containing only these
exons. Our results show that the exon 1a transcript variant was the
most abundantly expressed transcript in un-stimulated resting splenic
B cells (Figure 13B).
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Figure 13. Quantitative real time RT-PCR (RT-qPCR) for mCB2 mRNA
Expression in Resting Splenic B cells. A. Semi-quantitative RT-PCR of
the mCB2 transcripts using exon specific primers and 2 separate mouse B cell
samples. The samples were collected after 32 cycles of amplification and run
on a 2% agarose gel visualized with ethidium bromide. B. Using taqman
probes; RT-qPCR was performed to determine the major CB2 transcript
utilized in mouse B cells at basal transcription. Results were normalized with
β-actin and expressed as a ratio of CB2 transcript/β-actin. Data are means ±
S.E.M. of five independent experiments.
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Aim 2. Characterize the Cnr2 Promoter in B Cells

Bioinformatics Analysis for Core Promoter Elements Near the
TSSs
It has been well established that identification of the TSS will
lead to the location of the core promoter, which is usually -40 bp
upstream to +40 bp downstream of the TSS. The basic elements that
comprise the core promoter are the TATA-box, INR (Initiator), DPE
(downstream promoter element), and BRE (TFIIB recognition
elements) (41). Therefore, we performed a bioinformatics analysis for
the presence of consensus sequence of the core promoter elements in
the vicinity of our RACE TSSs to tentatively identify the structure and
location of the Cnr2 core promoter. Using GCG SeqWeb, we aligned
the 5’ ends of the RACE sequences with that of previously described
CB2 mRNA sequences (GenBank accession nos. NM009924 for mouse,
and NM001841 for human) as well as the Cnr2 genomic region
spanning -45 bp to +50 bp of the RACE TSSs (positions +1, Figure
13), followed by in silico analysis for core element consensus
sequences. For exon 1a, we identified an INR sequence spanning the
area -2 bp to +5 bp surrounding the TSS (+1), a TATA-like sequence
at position -25 bp as well as multiple DPEs and DCEs at positions
+10,18,31,36,38, and +44 bp. The RACE results for the exon 1b
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transcript identified 3 TSSs, which from this analysis appear to have
INR-like sequences. In addition, a GC/GAGA-box spanning 24 bp is
present that is -24, -25, -26 bp as well as multiple DPE sites at
+30,33,29, and +35 bp from its respective TSS. The exon 2 RACE
transcript has an INR-like sequence, a TATA-box at -21 bp as well as
DCE at +11 bp and a DPE at +25 bp (Figure 14A). The RACE
transcripts from human also contain an INR-like sequence, as well as a
TATA-box at -31 bp, a BREd -24 bp and a DPE at +35 bp (Figure 14B).
From this analysis it appears that the consensus sequences for core
promoter elements are in the vicinity of the TSSs identified by the 5’
RACE experiments. Furthermore, the analysis suggested that mCnr2
has three potential core promoters for the pre-initiation complex to
assemble for transcription initiation, whereas hCNR2 has a single
putative core promoter.
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Figure 14. Putative Core Promoter Elements Near the TSSs. The gene region spanning approximately -40 bp
to +40 bp of the TSSs was analyzed for core promoter elements. A. The putative core promoters of the three mCB2
transcripts. For exon 1b the numbers for the TSSs (+1) are color coordinated with their respective core promoter
element. B. The hCNR2 gene putative core promoter. INR, Initiator (consensus sequence YYANWYY). DPE,
Downstream promoter element (consensus sequence RGWCGTG) BREd, TFIIB recognition element downstream the
TATA-box (consensus sequence RTDKKKK).
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Bioinformatics Analysis to Identify Putative Promoters and cisSequences
It is well accepted that the promoter consists of two interacting
components; the core promoter, in which the basic transcription
factors join with Pol II at the TSS to form the pre-initiation complex
and the regulatory elements that are involved in activated
transcription (51). These regulatory elements consist of proximal
elements, next to the core promoter, and enhancers/repressors
elements, which can be located several kbs upstream or downstream
the TSS. These regulatory elements, known as cis-sequences are the
DNA binding sites for transcription factors. Identifying the Cnr2
promoter and cis-sequences will provide insight into how this gene is
regulated in B cells during different states of activation.
Bioinformatics has become a useful tool in identifying sequences
that may be involved in regulating gene transcription that can then be
experimentally tested. Therefore, to increase our understanding of the
functional regulatory regions that control CB2 transcription we utilized
several web-base programs to tentatively locate the Cnr2 promoter
and cis-sequences. Functional regulatory regions tend to be close to
the TSS, therefore our first analysis was to locate putative promoters
near our 5’ RACE TSSs. To accomplish this we used the Genomatix
suite to analyze 1 kb of the Cnr2 genomic sequence (obtain from
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GenBank) surrounding the TSSs for exons 1 and 2. The analysis
yielded two predicted promoter regions for the mCnr2 and one for the
hCNR2. The first mCnr2 predicted promoter is 690 bp and spans the
region -574 bp to +115 bp from the mCB2 exon 1a TSS (+1). The
second mCnr2 promoter is 601 bp and spans -362 bp to +238 bp from
the mCB2 exon 2 TSS (+1). The single hCNR2 predicted promoter is
601 bp spanning -406 bp to +135 bp of the TSS (+1).
To identify putative cis-sequences, we used the same 1 kb
genomic regions as above and the MatInspector program of the
Genomatix suite, which this analysis yielded numerous cis-sequences
that hampered us to decipher the true positives from the false.
Therefore, we used the process of phylogenetic footprinting, in which
ClustalW was used to align the entire Cnr2 gene of mouse and human
to find conserved regulatory regions. Alignment of the orthologous
genes paralleled the Genomatix promoter prediction for the exon 1
region (Figure 15A). In addition, the orthologous alignment of the
genomic region near the mouse exon 2 showed high conservation
between mouse and human suggesting the possibility of an exon 2 for
human CNR2, which the Genomatix analysis did not reveal (Figure
15B). Exon 1 and 2 regions were further analyzed using the Consite
web-base program for conserved cis-sequence regions. The exon 1
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alignment revealed conserved cis-sequences for Elk-1 and c-REL, as
well as DNA binding sites for STAT6 and NF-kBp50 for mouse, GATA
and STAT for human. Similar results were obtained for the exon 2
alignment indicating a conserved NF-kB, p65, c-REL cis-sequence and
single STAT6 DNA binding sites for both mouse and human (Figure
15). The results obtained from these analyses exemplified the
usefulness of employing bioinformatics as a tool to direct research in
locating candidate Cnr2 gene regulatory regions that can then be
experimentally tested for functionality, as well as guide future research
in understanding the interplay between the cis-sequences and transfactors that regulate Cnr2 in B cells.
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Figure 15. ClustalW Alignment of the Mouse and Human Putative
Promoters. Nucleotides highlighted in blue represent the conserved regions
of mCnr2 and hCNR2 enabled prediction of the promoter region and cissequences (labeled and underlined). The 5’ RACE TSSs (+1) are bold and
purple nucleotides represent the 5’ UTR exons.
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Cloning of the Putative Cnr2 Promoters
From the bioinformatics analysis, the regions surrounding the
TSSs for mouse exons 1 and 2 appeared to have core promoter
elements, as well as enhancer elements, therefore we wanted to
evaluate these regions for promoter activity. To test for promoter
activity, we used genomic DNA from purified B cells to PCR amplify
select regions of exon 1 (Figure 16A) spanning -359 bp to +205 bp of
exon 1a TSS (+1) as well as the region from -189 bp to +205 bp of
exon 2 TSS (+1). During PCR amplification, the Taq polymerase adds
an adenosine nucleotide at the end of elongation thereby creating an
A-tail that can be easily cloned into a TA-cloning vector, such as the
TOPO-blue vector. Therefore, the PCR amplified DNA fragments were
gel purified and initially TA-cloned into the TOPO-blue vector then subcloned into the pGL3-enhancer vector via the Hind III site by standard
methods (Figure 16B). PCR screening was performed to determine
insertion of the Cnr2 clones into the pGL3-enhancer vector (Figure
16C). In total, three exon 1; pGL3-E16(-270,+205), E19(+68,+205),
and E25(-359,+63) as well as five exon 2; pGL3-P7(-189,+36), P8(90,+36), P10(+13,+205), P11(-189,+101), and P13(-25,+101)
experimental Cnr2 clones were chosen for evaluation of promoter
activity.
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Figure 16. Cloning of the Exon 1 Promoter. A. PCR amplification of Cnr2
promoter regions TA-cloned into the TOPO-blue vector. B. Hind III digest of
TOPO- Cnr2 clones for sub-cloned into the pGL3-enhancer vector. C. PCR
amplification of Cnr2 clones in the pGL3-enhancer vector.
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Determination of Cnr2 Promoter Activity in B cells
The pGL3- Cnr2 constructs were transfected by electroporation
into IL-4/anti-CD40 stimulated primary B cells and 24 hrs later
luciferase activity was determined for each construct. For exon 1 five
constructs were analyzed, two control and three experimental vectors.
The pGL3-enhancer vector does not have a promoter and contains only
the SV40 enhancer downstream of the luciferase gene and therefore
served as baseline activity. The pGL3-control vector contains both the
SV40 promoter and enhancer and therefore exhibits full promoter
activity. The pGL3-E25 experimental vector spans the region -359 bp
to +63 bp (exon 1a, TSS +1) and contains all the TSSs and core
promoter elements for exons 1a and 1b. The pGL3-E16 experimental
vector spanning -270 bp to +205 bp contains the core promoter of
exon 1a and a portion of the exon 1b core promoter. The GAGA-box
and 1 TSS at -280 bp were excluded. The pGL3-E19 experimental
vector spans from +68 bp to +205 bp and therefore did not contain
either the exon 1a or exon 1b TSSs and core promoter cis-elements.
Luciferase activation analysis for the exon 1 putative promoter
demonstrated significant promoter activity for the pGL3-E25(359,+63), pGL3-E16(-270,+205) and pGL3-control vectors, but not
for pGL3-E19(+68, +205), indicating that the RACE TSSs we identified
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were in Cnr2 genomic regions that exhibited characteristics of a gene
promoter (Figure 17A). In addition, pGL3-E25 had greater promoter
activity then pGL3-E16 indicating that the GAGA-box and possibly the
TSS at -280 bp are important for full promoter activity under these
conditions.
The five exon 2 experimental clones used to evaluate promoter
activity were pGL3-P11, which spans the genomic region -189 bp to
+101 bp (exon 2, TSS +1) and contained the core and enhancer ciselements. The truncated pGL3-P7 spanned -189 bp to +36 bp, was
designed to exclude the 3’ NF-kBp65, cREL cis-elements yet contained
the core and 5’ enhancer cis-elements. The pGL3-P8 was further
truncated at the 5’end to span -90 bp to +36 bp and contained only
core promoter cis-elements along with the 5’ cREL enhancer ciselement. The pGL3-P13(-25,+101) truncated at the 5’ end to include a
third of the TATA-box and 3’ core and enhancer cis-elements. The
pGL3-P10(+13,+205) clone truncated at the 5’ end to exclude the
TATA-box and INR core cis-elements, but extended at the 3’ end to
include a portion of the GenBank designated exon 2 sequence. The
reporter assay for the exon 2 clones demonstrated that the core
promoter vector pGL3-P8 was sufficient to produce significant
promoter activity. However, increased promoter activity was seen with
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the pGL3-P7 clone, which contained the 5’ Sp1 cis-element as well as
the pGL3-P11 clone that contained the 5’ Sp1 and the 3’ NF-kBp65,
cREL cis-elements. No significant promoter activity was observed for
either the pGL3-P10 or -P13 clones demonstrating that the TATA-box
as well as the INR are needed for full promoter activity (Figure 17B).
In all, these results demonstrated that the Cnr2 genomic region
containing the TSSs as well as core promoter cis-elements for exons
1a, 1b and 2 contained strong promoter activity as judged by these
luciferase expression studies.
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Figure 17. pGL3-Cnr2 Luciferase Activity in IL-4/anti-CD40 Activated
B Cells. A. Exon 1 putative Cnr2 promoter pGL3-clones. B. Exon 2 putative
Cnr2 promoter pGL3-clones.
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Aim 3. To Determine CB2 Transcript Usage in Activated B Cells
as well as Other Immune Cell Subtypes

CB2 Transcript Expression in Mouse Activated B cells
Since CB2 is abundant in B cells and implicated in the
involvement of various B cell functions, an understanding of transcript
usage under varying conditions of B cell activation is of interest. The
literature shows that stimulation of B cells with anti-CD40 and/or IL-4,
through STAT6 (cis-sequence found in both CB2 putative promoter
regions) activation, increases CB2 expression (8) (25) (42), whereas,
LPS stimulation suppresses expression (26). LPS through TLR4 triggers
an intracellular signaling cascade, similar to anti-CD40/CD40 binding,
that activates the trans-regulatory factors Elk1 and NF-kB (found in
the CB2 putative promoters). Both IL4/anti-CD40 and LPS promote B
cell maturation and isotype switching.
Therefore, to gain a better understanding of CB2 transcipt usage
in activated B cells, we stimulated primary B cells with either LPS ornd
the co-stimulatory molecule anti-CD40. To determine the relative
expression of the CB2 transcript variants, total RNA was collected at 1,
3, and 8 hrs following stimulation for RT-qPCR analysis. We looked at
the expression of the CB2 coding exon (exon 3, Figure 18A) and
observed a steady increase over time following LPS stimulation.
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Furthermore, using exon-specific primers and taqman probes revealed
that LPS induced significant expression of the non-coding exon 1b and
2 transcripts, whereas, the exon 1a transcript remained at baseline
(Figure 18B).
B cells activated by IL-4 and anti-CD40 undergo class switch
recombination (CSR) changing the C region of the H chain to switch
from IgM to IgE. Our lab has previously shown that IL4/anti-CD40
stimulation increased CB2 expression in B cells at the message (25)
and protein level (1). In addition to this, our lab has also shown that
co-treatment of the IL-4/anti-CD40 stimulated B cells with the CBR
agonist CP55940 increased immunoglobulin class switching to IgE.
To determine the effective dose of IL-4, we initially looked at CB2
the coding exon 3 expression using two concentrations of IL-4 (3 and
10 ng/ml) with anti-CD40 (0.5 μg/ml). Exon 3 expression was
significantly higher in B cells stimulated with 3 ng/ml of IL-4 compared
to B cells stimulated with 10 ng/ml (Figure 19A). Therefore, we used
the 3 ng/ml concentration of IL-4 with anti-CD40 to investigate CB2
transcript variant expression. Following stimulation exon 3 increased
within the first hour and maintained a steady state of expression
thereafter (Figure 19A). On the other hand, non-coding exon
expression increased increased 1 hr following stimulation with exon 2
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continuing to increase over time, while the exons 1a and 1b returned
to baseline by three hrs post stimulation (figure 19B). These results
demonstrated for the first time that CB2 transcript usage differs in B
cells depending upon the state of activation of the cell with exon 1a
predominating under basal conditions and exons 1b and 2 under
varying conditions of activation.
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Figure 18. LPS Induces the Expression of the CB2 Exon 1b and 2
Transcripts in Primary B cells. Primary B cells were cultured for 1, 3, and
8 hrs in RPMI medium containing 5 μg/ml LPS. Total RNA was isolated and 1
μg was used for RT-qPCR A. Total CB2 message expression (exon 3)
increases over time with LPS stimulation. B. Exon 1b and 2 transcripts
expression is significantly increased overtime whereas the exon 1a transcript
remains at baseline. Results were obtained by the 2-ΔΔCT method in which βactin is the endogenous control and un-stimulated B cells (time 0) as the
calibrator. Data are means ± S.E.M. of three independent experiments. *
Significance at P = 0.05
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Figure 19. Primary B cells Stimulated with IL4 and anti-CD40. Primary
B cells were cultured for 1, 3, and 8 hrs in RPMI medium containing IL-4 and
500 ng/ml anti-CD40. Total RNA was isolated and 1 μg was used for RT-qPCR
A. Total CB2 expression (exon 3) significantly increases with 3 ng/ml
compared to 10 ng/ml IL-4 and 500 ng/ml anti-CD40. The exon 2 transcript
steadily increases with stimulation of 3 ng/ml IL-4.
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CB2 Transcript Expression in Immune Cell Subtypes
The bioinformatics analysis performed in Aim 1 of the GenBank
CB2 clones suggested that expression of the first 5’UTR exon (1 and 2)
variants could be related to tissue or cell type, the clones of immune
tissue expressed exon 1, and other tissue types expressed exon 2. In
spite of this, 5’ RACE showed that B cells expressed CB2 transcripts
containing two variants of exon 1 and a single exon 2 variant. Since
the previously described GenBank clones were obtained from immune
tissues, and provided no information on transcript expression in
immune cell subtypes, we wanted to investigate CB2 expression in
other immune cells other than B cells. Total RNA was isolated from
purified un-stimulated T cells, dendritic cells, and macrophages for 5’
RACE analysis. The results showed that CB2 transcript expression was
unique to immune cell subtypes. For example, T cells expressed only
the exon 1a variant, whereas dendritic cells and macrophages
expressed two transcript variants (exon 1a and 2). Most interesting
was that the exon 1b variant was only observed in B cells (Figure 20).
To confirm the expression of the transcript variants in the immune cell
subtypes, RT-qPCR using exon specific primers and taqman probes
was done (Figure 21). Coding exon 3 transcript expression was highest
in B cells, followed by dendritic cells, then macrophages and T cells
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expressing the least (Figure 21A). The exon 1a variant was the major
CB2 transcript seen in T cells. Dendritic cells and macrophages
expressed both the exon 1a and 2 variants, however the relative
expression of exon 2 was much higher in the dendritic cells (Figure
21B). The expression of the exon 1b variant was exclusive to B cells,
though a negligible amount was observed in dendritic cells, which
could be from amplification of residual genomic DNA. These results
showed for the first time that the CB2 transcript expression profile is
different among the immune cell subtypes and that variant expression
could be related to cell type and/or cell function. In addition, among
these immune cell subtypes, the exon 1b variant was observed only in
B cells and therefore could potentially be a cell specific target for CB2
expression in this cell type.
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Figure 20. Immune Cell Subtypes 5’ RACE CB2 Transcripts. Gel
electrophoresis of the RACE products isolated from Splenocytes, B cells , T
cells (top panel) dendritic cells and macrophages (bottom panel).
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Figure 21. Quantitative RT-qPCR of the CB2 Transcripts in Immune
Cell Subtypes. Using 1 μg of total RNA isolated from un-stimulated B cells, T
cells, Dendritic cells (DC) and macrophages (Mo) CB2 transcript usage was
determined. A. Total CB2 expression (exon 3) in the immune cell subtypes.
B. CB2 transcript expression in the immune cell subtypes.
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CB2 Transcript Expression in Development of B cells
In A recent study investigating CB2 mediation of immature B cell
retention in bone marrow sinusoids (37) showed a two-fold higher
expression of CB2 in immature B cells compared to pre-B cells and that
CB2 deficiency led to a lower frequency of the Ig light -chain (λ+)
immature and mature B cells in the blood and spleen, thus suggesting
a role for CB2 in the formation of the B cell repertoire. In addition the
results above have shown that expression of the CB2 transcript
variants can be related to immune cell subtype as well as the
activation state of B cells. Therefore, we investigated CB2 transcript
expression in three different B cell lines representing B cell
development from the pre-B stage to the mature stage.
The three mouse B cell lines used were; 18.81, an Abelson
virus-transformed pre-B cell line that synthesizes only H chain, no light
chain is produced. WEHI-231, an immature B lymphoma cell line that
lacks Fc receptors and expresses only surface IgM and not IgD. K46μ,
a mature B lymphoma cell line that expresses surface IgM and IgD.
The 5’ RACE of the different cell lines showed that the pre-B cell line
expressed the exon 1a transcript and that the immature B cell line
WEHI-231 and the mature B cell Line K46μ express all three
transcripts but at different levels (Figure 22A). Therefore, we
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performed RT-qPCR to determine the predominant CB2 transcript
expressed in these B cell lines. CB2 coding exon 3 was observed to be
the highest in WEHI-231 (immature) and lower in 18.81 and K46μ.
The predominant CB2 transcript observed in 18.81 and WEHI-231 was
the exon 1a transcript, whereas the exon 1b transcript was
predominant in the mature K46μ B cell line (Figure 22B). The data
suggested that expression of the CB2 transcript variants could be
related to the developmental stage of B cells. In addition these results
further support that CB2 transcript usage varies in response to changes
in B cell biology.
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Figure 22. CB2 Transcript Expression in B Cell Lines. A. Gel
electrophoresis of the 5’ RACE products present in the B cell lines. B. RTqPCR for CB2 transcript expression in the B cell lines.
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DISCUSSION

The relative robust expression of CB2 in human and mouse B
cells suggests that this receptor may have an important role in B cell
biology. However, only a few reports have investigated the function of
CB2 in B cells. Furthermore, examination of the CB2 transcript
expression and Cnr2 regulatory elements (i.e. promoter and TSS) in B
cells had not been reported. Therefore, we investigated the genomic
sequences involved in transcription of CB2 by identifying the TSSs,
mRNA transcripts and core promoter regions in purified resting and
activated mouse B cells.
Our data provide the first evidence that resting splenic B cells in
mice use multiple TSSs and express at least three CB2 transcript
variants. Based on present models of transcription initiation it is
possible that two mechanisms of transcription could be involved in the
generation of these variants: 1) alternative splicing of the 5’UTRs in
the case of exons 1 or 2, and in fact donor-acceptor sites occur in
these regions; and 2) alternative transcription initiation (dispersed
initiation, see below) generating exon 1 variants that differ in the
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length of their 5’ ends. The latter event may have occurred in the case
of exon 1 in that we observed different lengths of the 5’ ends ranging
over 295 bps and containing a cluster of four TSSs. Interestingly, a
cluster of TSSs was predicted by the database, DBTSS, in the 5’
flanking regions of exons 1 and 2; furthermore, multiple TSSs were
reported in GenBank CB2 clones from various tissues in these same
regions. Our RACE products from B cells identified new TSSs for exons
1 and 2 that were not only different than reported in other tissues but
for the most part longer at the 5’ ends. Because of these many TSSs
spread over hundreds of bps, we analyzed for core promoter
sequences in these areas using an in silico approach. Interestingly, we
found consensus core promoter sequences such as INR, DPE, DCE
along with either TATA or GC boxes in abundance and in proximity to
all of the TSSs expressed in mouse and the one TSS expressed in
human B cells (see Figure 14). However, although present, these
sequences were in different numbers and relative distances to the TSS
position suggesting heterogeneity in core promoter activity under
resting and activated conditions. Although the functional significance of
multiple TSSs and core promoters is unknown, previous studies
suggested this heterogeneity relates to cell type and/or cell activation
state. This was observed in studies on the control of alternative first
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exons of the glucocorticoid receptor (GR) which are under the control
of specific transcription factors that control both tissue specific and cell
activation state specific GR expression (49). This was also observed
with adenosine A2A receptor (A2AR) 5’UTR splice variants wherein the
long 5’UTR A2AR variants were observed in resting PMNs, whereas the
short 5’UTRs were expressed to a greater extent in LPS- stimulated
cells suggesting short 5’UTR variants were more efficiently translated
(23) and suggesting the length of the 5’UTR can be a factor in
determining tissue specificity and cell activation state.
In our mouse CB2 studies, different TSSs and transcript
expression were observed in different cell types. For example, resting
T cells expressed only the exon 1a variant (Figures 20 & 21) and
variants of this have been reported in thymocytes, splenocytes, and
the macrophage like cell line, NFS107 (GenBank accession nos.
AK037898, X86405, and NM009924). Whereas, bone and liver tissue
(GenBank accession nos. BC024052 and AK036658) expressed the exon
2 variant though shorter at the 5’end than what was observed in B
cells. Besides T cells, variation of CB2 transcript expression was
observed in other immune cell subtypes. For example, purified
dendritic cells and macrophages expressed the exon 1a and 2
variants(Figure 20), though in dendritic cells the expression of the two
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variants was more or less equal, whereas in macrophages the exon 1a
variant was expressed five-fold higher than the exon 2 variant (Figure
21). Furthermore, resting splenic B cells expressed 3 CB2 transcripts
with an expression rank order of exon 1a > exon 2 > exon 1b, and of
interest expression of the exon 1b variant was only observed in B cells
(Figures 13 and 21). This variation in transcript expression among the
various subtypes may be accounted for by variations in core promoter
activity surrounding the different TSSs.
In contrast to the multiple TSSs and transcript variants we saw
in mouse cells, human peripheral B cells collected from three different
donors expressed a single CB2 transcript and TSS (Figure 7).
Interestingly, our observations in mouse and human are in line with
those showing that two different strategies are employed by Pol II for
transcription initiation. The hCNR2 appears to utilize the more common
strategy termed “focused initiation” in which a single TSS and the core
promoter contains a TATA-box, BREd, INR, and DPE. On the other
hand, the mCnr2 is more like the second strategy that involves
multiple weak TSSs dispersed over DNA regions of approximately 50 to
150 bps, thereby dubbed “dispersed initiation” (21). The mechanisms
of dispersed initiation are not clear but probably involve selective
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usage of multiple upstream and downstream recognition and promoter
elements similar to what we observed surrounding the mouse TSSs.
Different mCB2 transcripts are not only associated with different
cell types but also with different cell activation states. Using RT-qPCR,
we showed that the mouse exon 1a transcript was predominantly
expressed in resting splenic B cells (Figure 13) but that exons 1b and
2 were more pronounced in the LPS-activated B cells (Figure 18B), and
that exon 2 increased in IL-4/anti-CD40 stimulated B cells (Figure
19B). A possible explanation of the observed variation in CB2 transcript
expression is the presence of proximal regulatory cis-sequences to the
transcript TSS. Because in addition to core promoter activity, cell
activation can lead to gene transcription through enhancer elements
on the DNA either 5’ or 3’ to the core promoter region (5).
Interestingly, the in silico analysis performed in Aim 2 identified
proximal NF-kB (-82 and +72 bp) as well as STAT6 (-6 and +12 bp)
cis-sequences 5’ and 3’ of the TSS(+1) for exon 2 (Figure 15B), which
may account for the observed increase expression of the exon 2
variant in B cells activated by LPS or IL-4/anti-CD40 since it is well
known that LPS, IL-4 and anti-CD40 activate B cells through an
increase in NF-kB (12, 44, 47) and with IL-4 through activation of
STAT6. In addition, pGL3-Cnr2 reporter plasmid transfected mouse B
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cells containing exon 2 genomic DNA constructs spanning -189 to
+101 bp showed strong promoter activity when stimulated with IL-4
and anti-CD40 antibodies (Figure 17B); non-stimulated cells showed
little luciferase activity (data not shown). Which the 5’ NF-kB cissequence appears to be important for promoter activation, because
constructs in which the 3’ NF-kB site has been omitted still exhibit
strong promoter activity (Figure 17B), in contrast to the much lower
activity observed reporter constructs in which the 5’ NF-kB site has
been deleted (Figure 17B). Furthermore, it is In addition to NF-kB,
STAT6 binding might also be involved in the significant increase of the
exon 2 transcript observed in B cells stimulated with IL-4/anti-CD40,
because two putative STAT6 sites are located at -6 and +12 bp of the
TSS(+1) of exon 2 (Figure 15B). However, as reported previously
(Thieu 2007), NF-kB may be required for binding of STAT6, supported
by the minimal to no promoter activity observed in the exon 2 reporter
constructs in which one or both STAT6 sites are present but the 5’ NFkB site has been deleted (Figure 17B). However, further analysis is
required to determine the Cnr2 regulatory relationship of these cissequences for the trans-factors under these conditions in B cells.
In addition to the variation of CB2 transcript expression seen in
activated B cells, differences in CB2 transcript expression was also
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observed in B cell development. RACE and RT-qPCR analysis of CB2
transcript expression in three mouse B cell lines representing different
stages of development showed that pre-B cells expressed only the
exon 1a variant, whereas immature and mature B cells express all
three variants, though at varying levels. Expression of the transcript
variants was greatest in the immature B cells, notably the exon 1a
variant, whereas mature B cells expressed mainly the exon 1b variant
(Figure 22). Our results are in line with a recent report in which CB2
transcript expression was higher in immature B cells located in bone
marrow sinusoids when compared to other developmental stages and
suggested a function for CB2 in the formation of the B cell repertoire
(Pereira 2009).
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SUMMARY

In summary, we have characterized for the first time multiple
TSSs that define alternative CB2 transcripts in mouse splenic B cells as
well as a single TSS and transcript in human PBMC B cells. We were
able to confirm by RT-PCR primer mapping, the relative location of the
TSS for mouse exons 1b and 2, as well as the human exon 1. These
experimentally defined TSSs directed further in silico analysis and
showed that these regions contain consensus sequences for multiple
elements such as TATA-box, INR and DPE. These elements were found
at the expected distances from the TSSs and by reporter assay
experiments these segments contained significant promoter activity
inferring that we correctly identified several of the TSSs in mouse B
cells as well as identify the location of two promoters. In addition, we
identified CB2 transcript usage in resting B cells as well as other
immune cell subtypes, in which the exon 1b transcript appears to be
unique to B cells and therefore may serve as a therapeutic target in B
cells. In addition, CB2 transcript expression was different in the mouse
B cell lines representing various maturation stages. Furthermore, we
80

identified CB2 transcript expression in LPS and IL-4/anti-CD40
activated B cells, in which the exon 1b and exon 2 variants appear to
be important.
The stimuli used in this study are known inducers of class switch
recombination (CSR) and previous work done in our lab has suggested
a role for CB2 receptor activation in enhancing IL-4/anti-CD40 CSR
from IgM to IgE, therefore it is possible from our work here, that exon
1b transcripts are unique to B cells and therefore provide a gene
target for suppressing CB2 expression in only B cells and not other
immune cell subtypes. The identification of the CB2 transcripts
expressed during these conditions will guide future studies in
regulating this receptor at the gene level, and provide possible gene
targets(i.e. RNA silencing) for the therapeutic application in
suppressing CB2 and IgE production in Allergic diseases.
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